Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM082 in Myopic Choroidal Neovascularization
NCT04222842Phase 1Suspended
- Sponsor
- AnewPharma Company, Ltd.
- Start
- Dec 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vorolanib in myopic choroidal neovascularization (mCNV), sponsored by AnewPharma Company, Ltd. Primary endpoints: Dose-Limiting Toxicity at 4 weeks and Adverse Events at 12 weeks. Started Dec 2019; status: suspended.
02
Drugs
vorolanib
03
Conditions
myopic choroidal neovascularization (mCNV)
Beyond the preview
Go deeper on NCT04222842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04222842.